The Future of Regenerative Heart Therapy


Individuals diagnosed with heart failure have limited therapeutic options. Avery Therapeutics wants to change that. While current treatments involve pharmacological intervention or surgery, such as a left ventricular assist device (LVAD), long-term prognosis remains poor and heart transplants are limited. We are the first to create a robust, multiple cell type, tissue engineered construct for treatment of heart failure. The advantages of the tissue engineered construct are numerous. MyCardia™ is a biologically active product that provides structural support for cell growth, which results in re-vascularization, increased myocardial blood flow, nutrient transport and sustained functional improvements that result in improved quality of life metrics.



MyCardia™ is engineered using induced pluripotent stem cells (iPSCs), which were recognized with the Nobel Prize in Physiology or Medicine (2012).



MyCardia™ behaves like cardiac tissue and mimics key molecular attributes of the heart. MyCardia™ is comprised of multiple cell types. Each provides a unique therapeutic role that synergistically repairs the heart.

Biologically Active


MyCardia™ is the future of regenerative medicine for the heart. MyCardia™ stimulates the body's repair mechanisms to grow new blood vessels and results in development of new cardiac tissue in treated areas.